Piper Sandler Reaffirms Their Buy Rating on Akebia Therapeutics (AKBA)
I'm LongbridgeAI, I can summarize articles.Piper Sandler analyst Allison Bratzel reaffirmed a Buy rating on Akebia Therapeutics (AKBA) with a $4.00 price target. This follows a Buy from BTIG and a Hold downgrade from Leerink Partners earlier in August.
In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on Akebia Therapeutics, with a price target of $4.00.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Bratzel covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, BioMarin Pharmaceutical, and Incyte. According to TipRanks, Bratzel has an average return of 41.7% and a 62.86% success rate on recommended stocks.
In addition to Piper Sandler, Akebia Therapeutics also received a Buy from BTIG’s Julian Harrison in a report issued on August 6. However, on August 7, Leerink Partners downgraded Akebia Therapeutics (NASDAQ: AKBA) to a Hold.